Controlled OCT4-SOX2-KLF4 Reprogramming for Safe Cell Rejuvenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for cellular rejuvenation, such as the use of the Yamanaka factors, can lead to teratoma formation and acute toxicity due to complete reprogramming to a pluripotent state, posing risks for in vivo applications where maintaining cellular identity is crucial.
Innovation Solution
The use of spatially and temporally controlled expression of OCT4, SOX2, and KLF4, without c-Myc, to rejuvenate cells by restoring epigenetic marks associated with youthfulness, thereby reversing aging without complete reprogramming, using inducible promoters and AAV delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complete reprogramming to pluripotent state is used for cellular rejuvenation, then cellular youthfulness and regenerative capacity are improved, but teratoma formation and acute toxicity occur
Solution Approach 1:
The patent applies partial reprogramming by using transient expression of Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) for limited time periods (e.g., 1-4 weeks) rather than complete permanent reprogramming. This partial action restores epigenetic marks and cellular youthfulness while avoiding the harmful effects of complete pluripotent conversion, such as teratoma formation. The controlled, temporary intervention achieves the desired rejuvenation effect without excessive action that would cause toxicity.
Solution Approach 2:
The patent implements periodic reprogramming cycles where Yamanaka factor expression is activated and then deactivated in repeated cycles. This periodic action allows cells to undergo rejuvenation during active phases while recovering and maintaining cellular identity during inactive phases, preventing the continuous harmful effects of complete reprogramming while maintaining regenerative capacity.
2Reliability
If Yamanaka factors are expressed to reverse epigenetic aging, then epigenetic marks are restored, but cellular identity is lost
Solution Approach 1:
The patent uses controlled, transient expression of Yamanaka factors to achieve partial epigenetic reprogramming. This partial action restores age-related epigenetic marks (such as DNA methylation patterns) without completely erasing cellular identity information. The limited duration and dosage of factor expression allow selective restoration of youthful epigenetic features while preserving tissue-specific gene expression programs.
Solution Approach 2:
The patent employs preliminary actions to maintain cellular identity during reprogramming, such as using inducible promoter systems that allow precise temporal control, and combining Yamanaka factor expression with identity-maintaining factors or inhibitors of complete dedifferentiation. This preliminary preparation prevents loss of cellular identity while enabling epigenetic restoration.
3Productivity
If continuous expression of reprogramming factors is used, then rejuvenation effect is enhanced, but toxicity and teratoma risk increase
Solution Approach 1:
The patent implements periodic reprogramming cycles with defined on/off phases. During on-phases, Yamanaka factors are expressed to enhance rejuvenation efficacy; during off-phases, expression is halted to reduce toxicity and teratoma risk. This periodic pattern maintains high productivity during active phases while minimizing harmful effects during inactive phases, achieving a balance between efficacy and safety.
Solution Approach 2:
The patent uses dynamic control systems such as inducible promoters (e.g., doxycycline-responsive systems) that allow real-time adjustment of reprogramming factor expression levels. This dynamic approach enables optimization of rejuvenation efficacy by increasing expression when needed while rapidly reducing expression to minimize toxicity, making the system adaptable to prevent teratoma formation and acute toxicity.
Data Source
AI summary
Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).